Communication of the diagnosis and information relating to ALS should be tailored to the needs of the patient and their family. Not all patients will want detailed information about prognosis straight away. Patients should be asked about their preferences for involving their family members and/or other carers. Both verbal and written information about symptoms, management (especially nutritional and respiratory support), and specific treatments should be provided.[11]Shoesmith C, Abrahao A, Benstead T, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ. 2020 Nov 16;192(46):E1453-68.
https://www.cmaj.ca/content/192/46/E1453
http://www.ncbi.nlm.nih.gov/pubmed/33199452?tool=bestpractice.com
[36]National Institute for Health and Care Excellence. Motor neurone disease: assessment and management. Jul 2019 [internet publication].
https://www.nice.org.uk/guidance/ng42
[63]van Eenennaam RM, Kruithof WJ, van Es MA, et al. Discussing personalized prognosis in amyotrophic lateral sclerosis: development of a communication guide. BMC Neurol. 2020 Dec 14;20(1):446.
https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-020-02004-8
http://www.ncbi.nlm.nih.gov/pubmed/33308184?tool=bestpractice.com
[72]Khan A, Frazer-Green L, Amin R, et al. Respiratory management of patients with neuromuscular weakness: an American College of Chest Physicians clinical practice guideline and expert panel report. Chest. 2023 Mar 13 [Epub ahead of print].
https://journal.chestnet.org/article/S0012-3692(23)00353-7/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/36921894?tool=bestpractice.com
All patients with ALS should be offered genetic testing, and both pre-test and post-test counselling. Pre-test counselling should cover personalised risk assessments and the range of possible outcomes, and prepare the patient for possible personal, psychological, and economical impacts of testing on themselves and family members. Post-test counselling allows the patient to discuss their result and the implications for them and their family.[24]Roggenbuck J, Eubank BHF, Wright J, et al. Evidence-based consensus guidelines for ALS genetic testing and counseling. Ann Clin Transl Neurol. 2023 Nov;10(11):2074-91.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646996
http://www.ncbi.nlm.nih.gov/pubmed/37691292?tool=bestpractice.com
Advance directives and wishes for end-of-life care should be discussed with the patient and family/carers as early as possible (but only when they are ready to do so), and long before hospice care is needed. Ongoing discussion of advanced care planning should be part of regular follow-up.[11]Shoesmith C, Abrahao A, Benstead T, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ. 2020 Nov 16;192(46):E1453-68.
https://www.cmaj.ca/content/192/46/E1453
http://www.ncbi.nlm.nih.gov/pubmed/33199452?tool=bestpractice.com
[36]National Institute for Health and Care Excellence. Motor neurone disease: assessment and management. Jul 2019 [internet publication].
https://www.nice.org.uk/guidance/ng42
[62]Taylor LP, Besbris JM, Graf WD, et al. Clinical guidance in neuropalliative care: an AAN position statement. Neurology. 2022 Mar 8;98(10):409-16.
https://n.neurology.org/content/98/10/409
http://www.ncbi.nlm.nih.gov/pubmed/35256519?tool=bestpractice.com
Patients who have feeding tubes and their carers should be instructed in their use: for example, how to prevent clogging.[129]Farrag K, Shastri YM, Beilenhoff U, et al. Percutaneous endoscopic gastrostomy (PEG): a practical approach for long term management. BMJ. 2019 Jan 22;364:k5311.
http://www.ncbi.nlm.nih.gov/pubmed/30670385?tool=bestpractice.com
The patient, and their family members and other carers, should be advised to seek immediate medical evaluation if the patient shows symptoms of severe respiratory dysfunction, especially when associated with fever.
Online information from recommended sources may be helpful for patients and families.
Motor Neurone Disease Association
Opens in new window
MND Scotland
Opens in new window
MDA (Muscular Dystrophy Association): ALS division
Opens in new window